Literature DB >> 15053780

Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice.

Hamid Daneshvar1, Paul Hagan, R Stephen Phillips.   

Abstract

An attenuated line of Leishmania mexicana (the L. mexicana H-line) has been established by culturing in vitro under gentamicin pressure. BALB/c mice infected with the L. mexicana H-line developed a CD4(+)Th1-like response, indicated by the cytokine profile of their splenocytes stimulated by L. mexicana wild-type (WT) promastigotes. This profile is sustained after these mice are challenged with L. mexicana WT. Control mice infected with L. mexicana WT alone developed a CD4(+)Th2-like cytokine profile. In mice immunized with L. mexicana H-line and then challenged with WT-line, were eliminated when immunizing H-line parasites persisted in the skin and draining popliteal lymph nodes (PLNs). In experiments in which mice were inoculated with attenuated and WT parasites at the same time, either at the same site or on separate sides of the mouse, growth of the WT parasites was significantly contained and controlled, indicating a possible therapeutic role for the attenuated parasites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15053780     DOI: 10.1111/j.0141-9838.2004.00671.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  5 in total

1.  Immune responses of NIH mice infected with avirulent and virulent strains of Plasmodium chabaudi adami single and mixed infections.

Authors:  M J Namazi; R S Phillips
Journal:  Korean J Parasitol       Date:  2010-03-18       Impact factor: 1.341

2.  UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.

Authors:  Siddhartha Kumar Bhaumik; Manoj Kumar Singh; Subir Karmakar; Tripti De
Journal:  Glycoconj J       Date:  2008-11-13       Impact factor: 2.916

3.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

4.  Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

Authors:  Néstor Sosa; Zeuz Capitán; Javier Nieto; Melissa Nieto; José Calzada; Hector Paz; Carmenza Spadafora; Mara Kreishman-Deitrick; Karen Kopydlowski; Diane Ullman; William F McCarthy; Janet Ransom; Jonathan Berman; Charles Scott; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2013-07-15       Impact factor: 2.345

Review 5.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.